Tactiva Therapeutics
Tactiva Therapeutics is an immuno-oncology company specializing in potent cancer immunotherapy using a dual T cell receptor approach. They develop next-generation adoptive cell therapy strategies that deliver robust and sustained immune attack on tumors by infusing patients with reprogrammed T cells, including a unique class of CD4 T cells that enhance anti-tumor responses. Their platform harnesses the synergistic effects of CD8-TCRs, CD4-TCRs, and hematopoietic stem cell-derived T cells to provide durable remission for cancer patients.
Industries
Nr. of Employees
small (1-50)
Tactiva Therapeutics
701 Ellicott Street, 4th Floor, Buffalo, NY 14203
Products
Dual enhanced adoptive cell therapy platform (dual TCR)
A therapeutic platform combining engineered CD4 and CD8 TCR-expressing cells and HSC-based approaches to provide direct CD4 cytotoxicity, sustained helper function, and long-term supply of anti-tumor T cells.
Licensed oncolytic viral asset armed with CXCR4 antagonist
Licensed intellectual property covering an oncolytic viral therapy engineered to deliver a CXCR4 antagonist, intended to inhibit cancer-initiating cells and modulate the tumor microenvironment.
Dual enhanced adoptive cell therapy platform (dual TCR)
A therapeutic platform combining engineered CD4 and CD8 TCR-expressing cells and HSC-based approaches to provide direct CD4 cytotoxicity, sustained helper function, and long-term supply of anti-tumor T cells.
Licensed oncolytic viral asset armed with CXCR4 antagonist
Licensed intellectual property covering an oncolytic viral therapy engineered to deliver a CXCR4 antagonist, intended to inhibit cancer-initiating cells and modulate the tumor microenvironment.
Services
Design and execution of early-stage clinical development programs, including basket trials across multiple tumor indications.
Acquisition and integration of external intellectual property and therapeutic assets (example: licensed oncolytic viral asset armed with a CXCR4 antagonist).
Partnership-based access to genomic expertise and health informatics to support discovery and development activities.
Design and execution of early-stage clinical development programs, including basket trials across multiple tumor indications.
Acquisition and integration of external intellectual property and therapeutic assets (example: licensed oncolytic viral asset armed with a CXCR4 antagonist).
Partnership-based access to genomic expertise and health informatics to support discovery and development activities.
Expertise Areas
- Adoptive cell therapy
- T cell receptor (TCR) engineering
- Hematopoietic stem cell engineering
- Oncolytic viral therapy
Key Technologies
- TCR engineering and transduction
- Adoptive T cell therapy
- HSC gene modification
- Oncolytic vaccinia virus therapy
News & Updates
Recognition for outstanding contributions to immune therapy and cancer research.
Recognition for outstanding contributions to immune therapy and cancer research.